Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database

BACKGROUND: Vascular endothelial growth factor (VEGF), tyrosine kinase (TK) and mechanistic target of rapamycin kinase (mTOR) inhibitors are common first-line (1 L) treatments for metastatic renal cell carcinoma (mRCC). Despite treatment availability, the 5-year survival rate in patients diagnosed a...

Descripción completa

Detalles Bibliográficos
Autores principales: Pal, Sumanta, Gong, Jun, Mhatre, Shivani K., Lin, Shih-Wen, Surinach, Andy, Ogale, Sarika, Vohra, Rini, Wallen, Herschel, George, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555983/
https://www.ncbi.nlm.nih.gov/pubmed/31174493
http://dx.doi.org/10.1186/s12885-019-5716-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555983/
https://www.ncbi.nlm.nih.gov/pubmed/31174493
http://dx.doi.org/10.1186/s12885-019-5716-z

Ejemplares similares